

Viral Vector CDMO Services

From design to GMP delivery



Flyer

Minaris Viral Vectors helps innovators advance in vivo and ex vivo viral vector programs from plasmid and vector design through process development, GMP manufacturing, integrated testing, release, and fill-finish. Based in Philadelphia,

the Minaris Viral Vectors Center of Excellence combines proven GMP execution, scalable platforms, and integrated testing capabilities to reduce handoffs, de-risk scale-up, and accelerate complex programs from construct to clinic.

At a Glance:

- 80+ GMP viral vector batches delivered across ex vivo and in vivo programs.
- Differentiated technologies: TESSA®, XOFLX®, off-the-shelf plasmid solutions, custom plasmid engineering, and a clonal HEK293 cell line with a DMF are designed to improve yield, quality, scalability, and COGs versus traditional approaches.
- Grade B CERs can accommodate aseptic processing that may reduce downstream losses.
- Integrated PD/AD, GMP manufacturing, testing, and lot release capabilities.
- Flexible workflows supporting client-owned processes or access to established Minaris solutions.

From Construct to Clinical Supply



Plasmid, Vector and
Cell Line Design



Process & Analytical
Development



Comprehensive
Tech Transfer



Integrated Testing Services



GMP Manufacturing
& Release



Viral Vector Expertise

Integrated viral vector capabilities spanning early development through GMP supply, including:



Lentiviral vectors
Transient, packaging, and producer cell-line approaches



In vivo and ex vivo applications
Vector supply for gene therapy and cell therapy programs



AAV vectors
Scalable development and manufacturing across transient and novel technologies



End-to-end workflow support
Integrated support from onboarding through GMP manufacturing and release



Plasmid technologies
OTS plasmids, plasmid design, optimization, and engineering support. Clinical-grade available with strategic partners



Cell banking
GMP MCB and WCB generation for reproducible viral vector manufacturing

Viral Vector Capabilities

One integrated partner. Fewer handoffs. Greater control from development to release.

Design & Optimize	Manufacture	Test & Release
Plasmid & vector design to identify and mitigate risks early	Viral vector manufacturing for ex vivo and in vivo programs	Integrated vector testing for development, GMP, and release
Construct optimization to improve yield, potency, and manufacturability	Scalable suspension manufacturing up to 1000L, with integrated fill-finish	Assay qualification support aligned to regulatory needs
Process & analytical development for scalable production and assay readiness	HEK293 and plasmid technologies to support process consistency	Co-located testing and manufacturing for timeline visibility
New technology assessments to improve product quality	Verification, engineering, and GMP runs designed to de-risk scale-up & clinical supply	Stability support for program continuity



The innovation engine behind our viral vector platforms.

OXGENE™ by Minaris brings advanced technologies in plasmid engineering, cell-line development, and viral vector production to help improve productivity, reduce complexity improve COGs, and support scalable LVV and AAV manufacturing.

- | **TESSA®** AAV production technology designed to support scalable, cost-effective AAV manufacturing through improved productivity and workflow efficiency
- | **XOFLX®** LVV stable cell line technology with both packaging and producer configurations to support more consistent, scalable, and efficient LVV production.
- | **Plasmid Engineering** Includes plasmid health checks, custom design, off-the-shelf plasmids, GOI silencing, and SnapFast™ backbones to identify design risks and
- | **HEK293 Cell Line** Clonal suspension HEK293 cell line with DMF to support consistent GMP vector production and regulatory needs..

Commitment to Quality

Vector manufacturing built for control, consistency, and regulatory readiness. Minaris supports viral vector programs with GMP manufacturing, integrated testing, vector-specific quality systems, and release strategies designed to support clinical progression and future commercialization globally.

Connect with us to advance your viral vector program
Whether you are optimizing an early construct, preparing for GMP manufacturing, or addressing vector supply constraints, Minaris Viral Vectors brings the technologies, expertise, and integrated capabilities to help move your program forward. Our viral vector manufacturing experience helps anticipate challenges, reduce risk, and enable your success from development through clinical supply.



FL-C-261113-1

©2026 Minaris Advanced Therapies, LLC. All Rights Reserved.

Get in Touch With Our Team Today



minaris.com/contact

